Bactolife Receives €30 Million Investment

Bactolife is a bio-industrial company developing proprietary Binding ProteinsTM that enhance the gut microbiome of humans and animals to reduce the burden of gastrointestinal infections and anti-microbial resistance. The company announced that it has received an investment of 30 million euros. The financing round was led by ATHOS with participation from the Bill & Melinda Gates Foundation and existing investors. Proceeds from the financing will allow Bactolife to advance its most mature projects towards commercial launch. It will also allow it to strengthen its technology platform and scale-up capabilities.

Also Read: Kraftblock Receives €20 Million Investment for Sustainability

Bactolife

Globally, there are more than 1.6 billion cases of diarrhoeal diseases annually. At best, this means stomach disorders. At worst, they can lead to life-threatening illnesses. Annual health costs are rising and there are limited options to prevent the disease manifestation in the first place. It is estimated that 760,000 children die annually from intestinal infections. At the same time, survivors suffer both subsequent infections and growth retardation. Today, most infections are treated with antibiotics, which are either very expensive or contribute to the spread of antibiotic-resistant bacteria. Bactolife is taking a unique approach to gut health for the good of people and animals by developing Binding Proteins™ that can reduce the risk of developing gut health infections. This reduces the need for antibiotics at an affordable price point.